Introduction: a market with no evidence behind it
Searching "best liver supplement" returns dozens of products — milk thistle, artichoke, curcumin, "liver detox" blends. The overwhelming majority have zero randomized controlled trials specifically in fatty liver disease (MASLD/NAFLD, metabolic dysfunction-associated steatotic liver disease).
Key thesis of the md_pereligyn protocol: of the entire "liver supplement" market, real placebo-controlled data in fatty liver disease exists for exactly three substances — vitamin E, silymarin, and N-acetylcysteine (NAC). I review the doses, trial duration, and the honest limitations of each.
| Substance | Dose | Duration |
|---|---|---|
| Vitamin E | 800 IU/day | 96 weeks |
| Silymarin | 2100 mg/day (700 mg×3) | 48 weeks |
| NAC | 600 mg twice daily | 3 months |
Vitamin E: the only agent with biopsy-confirmed benefit
The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo, N Engl J Med 2010;362:1675–1685, PMID 20427778) was a randomized placebo-controlled trial in non-diabetic patients with biopsy-confirmed NASH. Vitamin E at 800 IU/day for 96 weeks was the only arm to meet the prespecified primary histologic endpoint — improvement on a strict liver histology scoring system.
Limitations: the trial was conducted in non-diabetics. The evidence base is weaker in patients with type 2 diabetes. Long-term high-dose vitamin E (>400 IU/day) has been associated in other populations with a small increase in all-cause mortality and hemorrhagic stroke risk — the duration of use should be discussed with a physician, not treated as an unconditionally safe "just in case" supplement.
Silymarin (milk thistle): 2100 mg/day, 48 weeks
A randomized double-blind placebo-controlled trial in non-cirrhotic NASH patients (Clin Gastroenterol Hepatol, PMID 28419855) used silymarin 700 mg three times daily (2100 mg/day) for 48 weeks. Silymarin is a complex of six major flavonolignans from milk thistle (Silybum marianum) with antioxidant, anti-inflammatory, and antifibrotic effects in vitro.
Important: this is a smaller evidence base than vitamin E's, and not a biopsy-primary endpoint of the same scale. Silymarin is a rational, but not first-line, option — its traditional reputation as a "liver remedy" is broader than the volume of controlled data specifically in MASLD.
N-acetylcysteine (NAC): 600 mg twice daily, a signal from a small trial
A controlled trial (Khoshbaten M, et al., Hepat Mon, PMID 22308119) compared NAC 600 mg twice daily to vitamin C 1000 mg twice daily in 30 patients with fatty liver disease over 3 months. NAC significantly reduced ALT and spleen size compared to vitamin C.
This is a small-scale trial (n=30) — a strong mechanistic signal (NAC is a precursor to glutathione, the liver's key antioxidant), not grounds for strong claims. Larger MASLD trials are ongoing.
Protocol and monitoring
▸ Baseline diagnostics: ALT, AST, FIB-4 (see ALT without symptoms: silent liver diseases) — supplements without a baseline fibrosis assessment are not meaningful.
▸ 7-10% weight loss — the first-line intervention with the largest proven effect on histology (Vilar-Gomez 2015).
▸ Vitamin E 800 IU/day — discuss with a physician for confirmed non-diabetic NASH, recheck at 3-6 months.
▸ Silymarin 2100 mg/day (700 mg×3) — an alternative or addition, recheck ALT/AST at 8-12 weeks.
▸ NAC 600 mg twice daily — for intolerance to other options or as an addition, understanding the limited evidence base.
▸ Recheck at 3-6 months — ALT, AST, and FibroScan if available.
What is NOT proven
▸ "Liver detox" blends without named active ingredients at studied doses — a marketing category, not a clinical one.
▸ Artichoke, curcumin for MASLD — mechanistically plausible, but without RCTs of comparable scale specifically in fatty liver disease.
▸ High-dose vitamin E "just in case" — the PIVENS trial does not support benefit from continuing beyond the studied protocol; risks in other populations warrant physician discussion, not indefinite self-supplementation.
When to seek care
▸ ALT persistently above 30 U/L (men) / 19 U/L (women) not explained by alcohol or viral hepatitis.
▸ Confirmed MASLD/NASH with metabolic risk factors (obesity, diabetes, dyslipidemia) — discuss vitamin E, silymarin, or NAC as part of a comprehensive protocol.
▸ FIB-4 in the gray zone (1.3–2.67) — referral for FibroScan before choosing supplements.
I assess fatty liver disease stage (ALT, AST, FIB-4, FibroScan referral when indicated) and build a protocol based on actual trial evidence, not marketing claims.
Conclusion
Of the broad "liver supplement" market, controlled data in fatty liver disease exists for three substances: vitamin E 800 IU/day (the strongest evidence base, biopsy-confirmed, non-diabetics only), silymarin 2100 mg/day, and NAC 600 mg twice daily (smaller-scale but real RCTs). None replaces 7-10% weight loss — the intervention with the largest proven effect on liver histology.
This article is for informational purposes and does not replace consultation with a physician. Discuss any nutraceutical plan with your treating physician before starting, especially with diabetes, anticoagulant use, or planned use beyond a few months.
Sources
▸ Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). N Engl J Med 2010;362:1675–1685. PMID 20427778
▸ A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. PMID 28419855
▸ Khoshbaten M, et al. N-Acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat Mon 2010. PMID 22308119
▸ Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015. PMID 25865049
Related article: ALT without symptoms: silent liver diseases.
